Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities
{{output}}
Castration-resistant prostate cancer (CRPC) remains a difficult clinical problem, although androgen deprivation therapy and next-generation androgen receptor (AR) pathway inhibitors have greatly improved patient treatment. CRPC is not simply an androgen-indepe... ...
